Aprea Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $7.0M | $9.4M | $7.6M | $16.4M | $23.9M |
| Operating expenses | $13.5M | $15.8M | $16.1M | $113.4M | $37.4M |
| Operating income | -$13.2M | -$14.3M | -$15.5M | -$113.4M | -$37.4M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M |
| Balance Sheet | |||||
| Cash and equivalents | $14.6M | $22.8M | $21.6M | $28.8M | $53.1M |
| Current assets | $15.6M | $23.6M | $22.5M | $30.2M | $56.6M |
| Total assets | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M |
| Current liabilities | $2.8M | $3.4M | $4.4M | $3.2M | $7.3M |
| Total liabilities | — | — | — | $3.2M | $7.3M |
| Stockholders' equity | $12.4M | $19.3M | $17.0M | $25.6M | $49.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$12.9M | -$13.6M | -$12.2M | -$25.0M | -$37.7M |
| Depreciation and amortization | $21,715 | $22,318 | $7,052 | $4,403 | $12,829 |
| Capital expenditure | — | $15,478 | $93,093 | — | — |
| Free cash flow | — | -$13.6M | -$12.3M | — | — |
Shares outstanding 12.4M · Free float 50.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.